Navigation Links
KV Pharmaceutical Reports Record Revenues for Fiscal 2008 Third Quarter and Year-to-Date on a Preliminary Basis
Date:2/27/2008

kvpharmaceutical.com.

Safe Harbor

The information in this release may contain various forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995 ("PSLRA") and which may be based on or include assumptions concerning KV's operations, future results and prospects. Such statements may be identified by the use of words like "plans", "expects", "aims", "believes", "projects", "anticipates", "commits", "intends", "estimate", "will", "should", "could" and other expressions that indicate future events and trends.

All statements that address expectations or projections about the future, including without limitation, statements about the Company's strategy for growth, product development, product launches, regulatory approvals, market position, market share increases, acquisitions, revenues, expenditures and other financial results, are forward-looking statements.

All forward-looking statements are based on current expectations and are subject to risk and uncertainties. In connection with the "safe harbor" provisions, KV provides the following cautionary statements identifying important economic, political and technology factors, which among others, could cause actual results or events to differ materially from those set forth or implied by the forward-looking statements and related assumptions.

Such factors include (but are not limited to) the following: (1) changes in the current and future business environment, including interest rates and capital and consumer spending; (2) the difficulty of predicting FDA approvals, including timing, and that any period of exclusivity may not be realized; (3) acceptance and demand for new pharmaceutical products; (4) the impact of competitive products and pricing, including as a result of so-called authorized-generic drugs; (5) new product development and launch, including the possibility that any product launch may be delayed or that product ac
'/>"/>

SOURCE KV Pharmaceutical Company
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine news :

1. Acura Pharmaceuticals, Inc. Announces Andrew Reddick, President & CEO, To Take Medical Leave and Appointment of Richard Markham as Chairman of the Board
2. Idenix Pharmaceuticals to Present at the SIGnificant Investment Options in Healthcare Conference
3. VIA Pharmaceuticals to Present at Susquehanna and Rodman & Renshaw Conferences on March 4, 2008
4. Lotus Pharmaceuticals Raises $5 Million in Private Placement
5. Galderma Reaches Agreement to Acquire CollaGenex Pharmaceuticals
6. Transcept Pharmaceuticals to Present at the Susquehanna Financial Groups SIGnificant Investment Options in Healthcare Conference
7. Onyx Pharmaceuticals Reports Fourth Quarter and Twelve-Month 2007 Financial Results
8. RHEI Pharmaceuticals Licenses Attental From MethaPharma (Vemedia Group) for Distribution Throughout Asia
9. Onyx Pharmaceuticals Announces a Teleconference and Webcast to Provide an Update on Nexavar; Previously Announced Fourth Quarter and Full Year 2007 Financial Results Teleconference Rescheduled
10. 60 Minutes to Report on Dangers of Trasylol: Cory Watson Crowder & DeGaris Involved in Litigation Against Pharmaceutical Giant Bayer AG
11. KV Pharmaceutical Company Completes Unaudited Fiscal 2007 Results; Receives Trading Extension From NYSE
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2008)...Colo., Nov. 21 Heska Cor...l present at the New York Society of,Security Ana...nference on,December 2, 2008 at 1177 Avenue of th...tation is scheduled to begin at 9:35 a.m. Eastern ...ble via live webcast and for two weeks,following ...
(Date:11/21/2008)...chers remain cautious about future antibiotic resi... Nov. 21 (HealthDay News) -- People with moderate ...OPD) may be able to reduce the frequency of exacer...tibiotic, a new report says. , The study, publ...ican Journal of Respiratory and Critical Care Medi...
(Date:11/21/2008)...ov. 21 The University ...beginning of a collaborative effort to eradicate b... Breast Cancer Awareness and Research of the Ameri...ady of the United States, and Vivian Fernandez de ...ning M. D. Anderson in the initiative are the U.S....
(Date:11/21/2008)...eholders Intend To Vigorously Protect Investment A..., Nov. 21 Dr. Stephen J...amendment to their Schedule 13D with the U.S. Secu...sly filed a 13D disclosing ownership of 11.4% of L...77 LasikPlus fixed-site laser vision correction ce...
Breaking Medicine News(10 mins):Health News:Long-Term Erythromycin Cut COPD Complications 2Health News:First Lady Laura Bush's Partnership for Breast Cancer Awareness and Research Extends to Panama 2Health News:First Lady Laura Bush's Partnership for Breast Cancer Awareness and Research Extends to Panama 3Health News:Founders & Former Executive Management Team of LCA-Vision Seek Change to Rescue Company 2Health News:Founders & Former Executive Management Team of LCA-Vision Seek Change to Rescue Company 3Health News:Founders & Former Executive Management Team of LCA-Vision Seek Change to Rescue Company 4Health News:Founders & Former Executive Management Team of LCA-Vision Seek Change to Rescue Company 5Health News:Founders & Former Executive Management Team of LCA-Vision Seek Change to Rescue Company 6Health News:Founders & Former Executive Management Team of LCA-Vision Seek Change to Rescue Company 7
...deo, designed to increase emotional well-being and...creased knowledge but did not change behavior or e...y succeeded in increasing patients' knowledge of m...ty of adaptive devices and techniques, it did not ...
...tion to treat kleptomania has failed to find any c...stealing disorder,// according to researchers at t... results leave open the possibility that some medi..., may still be an effective treatment for certain ...
...hat as many as 25 percent of all patients admitted...monia, which can be fatal. // Ventilator-associate...ospital, and studies have shown that this infectio...and double the length of stay of the patient in th...
... Wisconsin is running a pioneering trial of using ...sults of which have //been "encouraging". Amish R... his team of cardiologists began their trial on Ma...cells for cardiac disease) works, it could revolut...
Other Medicine News:Health News:Educational Video Increases Knowledge but Not Behavior 2Health News:Educational Video Increases Knowledge but Not Behavior 3Health News:Study Finds No Conclusive Benefit from Treating Kleptomania 2Health News:Patients Own Dental Plaque may Cause Ventilator-associated Pneumonia 2
(Date:11/20/2008)...Calif., Nov. 20 Bionovo,...l present results from the Phase 1B,clinical tria...atic breast,cancer, BZL101, at the Society for In...ce in Atlanta, Georgia. The Company,s oral presen... will be presented as a part of the Best of the,S...
(Date:11/20/2008)...ass., Nov. 20 Radius Health ("Radi...nal $15 million to its second institutional financ... $82.5 million and the total amount raised since t...ting institutional investors participated in the f... including MPM Capital, The Wellcome Trust, Health...
(Date:11/20/2008)... 20 PAREXEL Internationa...biopharmaceutical services provider, today announc...rovide regulatory consulting and clinical research...e, PAREXEL now has locations throughout five impor...hich also include Argentina, Brazil, Chile, and Me...
(Date:11/19/2008)...O, Nov. 19 Posit Science Corporati...the Society for Neuroscience,Annual Conference in...e,training may benefit Baby Boomers. The compute...m (TM) uses adaptive exercises that target auditor...ed to drive generalized,improvements in cognition...
Breaking Medicine Technology:Bionovo Presents Positive Results from Phase 1B Trial of BZL101 for Metastatic Breast Cancer at the Society for Integrative Oncology 2Bionovo Presents Positive Results from Phase 1B Trial of BZL101 for Metastatic Breast Cancer at the Society for Integrative Oncology 3Bionovo Presents Positive Results from Phase 1B Trial of BZL101 for Metastatic Breast Cancer at the Society for Integrative Oncology 4Bionovo Presents Positive Results from Phase 1B Trial of BZL101 for Metastatic Breast Cancer at the Society for Integrative Oncology 5Radius Raises Additional $15 Million, Increasing Second Private Equity Financing Round to $82.5 Million 2PAREXEL Strengthens Leading Presence in Latin America With a New Location in Peru 2PAREXEL Strengthens Leading Presence in Latin America With a New Location in Peru 3PAREXEL Strengthens Leading Presence in Latin America With a New Location in Peru 4New Evidence That Brain-Plasticity Based Training has Broad Impact: Improved Cognition in Boomers, Improved Motor Control in Older Adults 2Breast cancer more aggressive among obese women 14374 1Breast cancer more aggressive among obese women 14374 2News from the March 2008 American Physical Society Meeting 3967 1News from the March 2008 American Physical Society Meeting 3967 2News from the March 2008 American Physical Society Meeting 3967 3News from the March 2008 American Physical Society Meeting 3967 4News from the March 2008 American Physical Society Meeting 3967 5Genmab and PDL BioPharma Close Sale of Antibody Manufacturing Facility 3963 1Genmab and PDL BioPharma Close Sale of Antibody Manufacturing Facility 3963 2Quaker 28R 29 Life 28R 29 Cereal Partners with Actress and Mom Holly Robinson Peete to Inspire Moms to Make Their Best Days Happen 14371 1Quaker 28R 29 Life 28R 29 Cereal Partners with Actress and Mom Holly Robinson Peete to Inspire Moms to Make Their Best Days Happen 14371 2Quaker 28R 29 Life 28R 29 Cereal Partners with Actress and Mom Holly Robinson Peete to Inspire Moms to Make Their Best Days Happen 14371 3
For the qualitative detection of single and multiple drugs and drug metabolites in human urine
For the qualitative detection of single and multiple drugs and drug metabolites in human urine
For the qualitative detection of cardiac troponin I (cTnl) in human whole blood and serum specimens
For the qualitative differential detection of circulating Plasmodium falciparum (P.f) antigen and an antigen that is common to all four species of malaria:plasmodium falciparum (P.f), plasmodium viv
Medicine Products: